OPKO Health, Inc. (OPK)

1,2700 +0,0500 (+4,10%) Al cierre: 04:00PM EDT

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305 575 4100
https://www.opko.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 3930

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Phillip Frost Ph.D.	Chairman & CEO	1,45M	N/A	1936
Dr. Jane H. Hsiao M.B.A., Ph.D.	Vice Chairman & Chief Technical Officer	1,36M	N/A	1947
Dr. Elias Adam Zerhouni M.D.	President & Vice Chairman	1,36M	N/A	1951
Mr. Adam E. Logal	Senior VP, CFO, Chief Accounting Officer & Treasurer	1,09M	N/A	1978
Mr. Steven D. Rubin Esq., J.D.	Executive VP of Administration & Director	1,22M	N/A	1960
Dr. Akhtar Ashfaq FACP, FASN, M.D.	Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal	N/A	N/A	N/A
Dr. Gary J. Nabel M.D., Ph.D.	Chief Innovation Officer & Director	N/A	N/A	1955
Dr. Charles W. Bishop	Chief Executive Officer of OPKO Renal	N/A	N/A	1952
Dr. Antonio F. Cruz	President of Transition Therapeutics	N/A	N/A	1953
Mr. Hans Berner	President of OPKO Health Iberoamerica	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Gobierno corporativo

El ISS Governance QualityScore de OPKO Health, Inc., a día 29 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 7; Tablero: 10; Derechos de los accionistas: 3; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.